Home
Live Updates
Dr Johnson on the Initial Efficacy of Ifinatamab Deruxtecan in Refractory SCLC : vimarsana.com
Dr Johnson on the Initial Efficacy of Ifinatamab Deruxtecan in Refractory SCLC
Melissa L. Johnson, MD, discusses findings from a subgroup analysis of outcomes with ifinatamab deruxtecan in patients with refractory small cell lung cancer, which she presented at the 2023 IASLC World Conference on Lung Cancer.
Related Keywords
Melissal Johnson ,
,
Oncology Department ,
Lung Cancer Research ,
Sarah Cannon Research Institute ,
Tristar Centennial Medical Center ,
Medical Executive Committee ,
D ,
Patients With Small Cell Lung Cancer ,
Infinatamab Deruxtecan ,
I Dxd Ds 7300 ,
2023 Iaslc World Conference On Lung Cancer ,
vimarsana.com © 2020. All Rights Reserved.